These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29109911)

  • 61. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
    Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J; ; Williams RT; Flemming C; Lambrechts D; Despierre E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching P; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Nakanishi T; Yatabe Y; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan J; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut J; Iversen E; Weber RP; Berchuck A; Goode E; Bowtell DD; Chenevix-Trench G; deFazio A; Norris MD; MacGregor S; Haber M; Henderson MJ
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957074
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.
    Spizzo G; Went P; Dirnhofer S; Obrist P; Moch H; Baeuerle PA; Mueller-Holzner E; Marth C; Gastl G; Zeimet AG
    Gynecol Oncol; 2006 Nov; 103(2):483-8. PubMed ID: 16678891
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer.
    Richards EJ; Permuth-Wey J; Li Y; Chen YA; Coppola D; Reid BM; Lin HY; Teer JK; Berchuck A; Birrer MJ; Lawrenson K; Monteiro AN; Schildkraut JM; Goode EL; Gayther SA; Sellers TA; Cheng JQ
    Oncotarget; 2015 Oct; 6(33):34745-57. PubMed ID: 26430965
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The role and expression of miR-100 and miR-203 profile as prognostic markers in epithelial ovarian cancer.
    Azizmohammadi S; Azizmohammadi S; Safari A; Kosari N; Kaghazian M; Yahaghi E; Seifoleslami M
    Am J Transl Res; 2016; 8(5):2403-10. PubMed ID: 27347348
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
    Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
    [TBL] [Abstract][Full Text] [Related]  

  • 66. HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3.
    Dong S; Wang R; Wang H; Ding Q; Zhou X; Wang J; Zhang K; Long Y; Lu S; Hong T; Ren H; Wong K; Sheng X; Wang Y; Zeng Y
    J Exp Clin Cancer Res; 2019 Mar; 38(1):110. PubMed ID: 30823895
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.
    Ma RQ; Tang ZJ; Ye X; Cheng HY; Sun KK; Chang XH; Cui H
    Arch Gynecol Obstet; 2018 May; 297(5):1235-1244. PubMed ID: 29428978
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.
    Mardas M; Stelmach-Mardas M; Madry R
    Support Care Cancer; 2017 Mar; 25(3):795-800. PubMed ID: 27771784
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effect of body mass index on survival in advanced epithelial ovarian cancer.
    Bae HS; Hong JH; Ki KD; Song JY; Shin JW; Lee JM; Lee JK; Lee NW; Lee C; Lee KW; Kim YM
    J Korean Med Sci; 2014 Jun; 29(6):793-7. PubMed ID: 24932080
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Serum relaxin as a diagnostic and prognostic marker in patients with epithelial ovarian cancer.
    Guo X; Liu Y; Huang X; Wang Y; Qu J; Lv Y
    Cancer Biomark; 2017 Dec; 21(1):81-87. PubMed ID: 29060928
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Socioeconomic status and epithelial ovarian cancer survival in Sweden.
    Weiderpass E; Oh JK; Algeri S; Bellocco R
    Cancer Causes Control; 2014 Aug; 25(8):1063-73. PubMed ID: 24906473
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic value of preoperative serum bilirubin levels in ovarian cancer.
    Xi XX; Wang HL; Chen T; Dai JR; Hou SY; Chen YG
    Am J Transl Res; 2020; 12(5):2267-2280. PubMed ID: 32509218
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.
    Gong W; Liu Y; Seidl C; Diamandis EP; Kiechle M; Drecoll E; Kotzsch M; Magdolen V; Dorn J
    BMC Cancer; 2019 Jul; 19(1):696. PubMed ID: 31307411
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.
    Dholariya S; Mir R; Zuberi M; Yadav P; Gandhi G; Khurana N; Saxena A; Ray PC
    Clin Transl Oncol; 2016 Jan; 18(1):73-81. PubMed ID: 26209050
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.
    Gasimli K; Braicu EI; Richter R; Chekerov R; Sehouli J
    Ann Surg Oncol; 2015 Aug; 22(8):2729-37. PubMed ID: 25672560
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic Impact of ABO Blood Group on the Survival in Patients with Ovarian Cancer.
    Zhou J; Yang LC; He ZY; Li FY; Wu SG; Sun JY
    J Cancer; 2015; 6(10):970-5. PubMed ID: 26316893
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
    J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
    Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Secondary cytoreduction for relapsed ovarian cancer - Authors' reply.
    Chen Y; Shi T; Liu J; Zhu J; Zang R
    Lancet Oncol; 2021 Jun; 22(6):e233. PubMed ID: 34087142
    [No Abstract]   [Full Text] [Related]  

  • 80. A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
    Shi T; Yin S; Zhu J; Zhang P; Liu J; Zhu Y; Wu S; Chen X; Wang X; Teng Y; Zhu T; Yu A; Zhang Y; Feng Y; Huang H; Bao W; Li Y; Jiang W; Zhang P; Li J; Ai Z; Zhang W; Jia H; Zhang Y; Jiang R; Zhang J; Gao W; Luan Y; Zang R
    J Gynecol Oncol; 2020 May; 31(3):e61. PubMed ID: 32319233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.